Identification of Key Immune-Related Genes in the Treatment of Heart Failure After Myocardial Infarction with Empagliflozin Based on RNA-Seq

References

• Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128(10):1421–1434. doi:10.1161/CIRCRESAHA.121.318172
   PubMed Web of Science ®Google Scholar
• Peet C, Ivetic A, Bromage DI, et al. Cardiac monocytes and macrophages after myocardial infarction. Cardiovasc Res. 2020;116(6):1101–1112. doi:10.1093/cvr/cvz336
   PubMed Web of Science ®Google Scholar
• Wu X, Reboll MR, Korf-Klingebiel M, et al. Angiogenesis after acute myocardial infarction. Cardiovasc Res. 2021;117(5):1257–1273. doi:10.1093/cvr/cvaa287
   PubMed Web of Science ®Google Scholar
• Jenča D, Melenovský V, Stehlik J, et al. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Fail. 2021;8(1):222–237. doi:10.1002/ehf2.13144
   PubMed Web of Science ®Google Scholar
• Houssari M, Dumesnil A, Tardif V, et al. Lymphatic and immune cell cross-talk regulates cardiac recovery after experimental myocardial infarction. Arterioscler Thromb Vasc Biol. 2020;40(7):1722–1737. doi:10.1161/ATVBAHA.120.314370
   PubMed Web of Science ®Google Scholar
• Murphy A, Goldberg S. Mechanical Complications of Myocardial Infarction. Am J Med. 2022;135(12):1401–1409. doi:10.1016/j.amjmed.2022.08.017
   PubMed Web of Science ®Google Scholar
• Gong FF, Vaitenas I, Malaisrie SC, et al. Mechanical complications of acute myocardial infarction: a review. JAMA Cardiol. 2021;6(3):341–349. doi:10.1001/jamacardio.2020.3690
   PubMed Web of Science ®Google Scholar
• Strassheim D, Dempsey EC, Gerasimovskaya E, et al. Role of inflammatory cell subtypes in heart failure. J Immunol Res. 2019;2019(2164017):1–9. doi:10.1155/2019/2164017
   Google Scholar
• Heinrichs M, Ashour D, Siegel J, et al. The healing myocardium mobilizes a distinct B-cell subset through a CXCL13-CXCR5-dependent mechanism. Cardiovasc Res. 2021;117(13):2664–2676. doi:10.1093/cvr/cvab181
   PubMed Web of Science ®Google Scholar
• Tang Y, Zeng X, Feng Y, et al. Corrigendum: association of systemic immune-inflammation index with short-term mortality of congestive heart failure: a retrospective cohort study. Front Cardiovasc Med. 2022;9:1116547.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Empagliflozin: a review in symptomatic chronic heart failure. Drugs. 2022;82(16):1591–1602. doi:10.1007/s40265-022-01778-0
   PubMed Web of Science ®Google Scholar
• Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819–829. doi:10.1016/S0140-6736(20)31824-9
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. doi:10.1056/NEJMoa2107038
   PubMed Web of Science ®Google Scholar
• Xu L, Nagata N, Nagashimada M, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137–149.
   PubMed Web of Science ®Google Scholar
• Meng Z, Liu X, Li T, et al. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway. Int Immunopharmacol. 2021;94(107492):107492. doi:10.1016/j.intimp.2021.107492
   PubMedGoogle Scholar
• Kolijn D, Pabel S, Tian Y, et al. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation. Cardiovasc Res. 2021;117(2):495–507. doi:10.1093/cvr/cvaa123
   PubMed Web of Science ®Google Scholar
• Saeidian AH, Youssefian L, Vahidnezhad H, et al. Research techniques made simple: whole-transcriptome sequencing by RNA-Seq for diagnosis of monogenic disorders. J Invest Dermatol. 2020;140(6):1117–1126.e1111. doi:10.1016/j.jid.2020.02.032
   PubMed Web of Science ®Google Scholar
• Nakao M, Shimizu I, Katsuumi G, et al. Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload. Sci Rep. 2021;11(1):18384. doi:10.1038/s41598-021-97787-2
   PubMed Web of Science ®Google Scholar
• Zhu Y, Chen X, Guo L, et al. Acute sleep deprivation increases inflammation and aggravates heart failure after myocardial infarction. J Sleep Res. 2022;31(6):e13679. doi:10.1111/jsr.13679
   PubMed Web of Science ®Google Scholar
• Sun D, Yang F. Metformin improves cardiac function in mice with heart failure after myocardial infarction by regulating mitochondrial energy metabolism. Biochem Biophys Res Commun. 2017;486(2):329–335. doi:10.1016/j.bbrc.2017.03.036
   PubMed Web of Science ®Google Scholar
• Emmons-Bell S, Johnson C, Roth G. Prevalence, incidence and survival of heart failure: a systematic review. Heart. 2022;108(17):1351–1360. doi:10.1136/heartjnl-2021-320131
   PubMed Web of Science ®Google Scholar
• Del Buono MG, Moroni F, Montone RA, et al. Ischemic cardiomyopathy and heart failure after acute myocardial infarction. Curr Cardiol Rep. 2022;24(10):1505–1515. doi:10.1007/s11886-022-01766-6
   PubMed Web of Science ®Google Scholar
• Andreadou I, Cabrera-Fuentes HA, Devaux Y, et al. Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. Cardiovasc Res. 2019;115(7):1117–1130. doi:10.1093/cvr/cvz050
   PubMed Web of Science ®Google Scholar
• Ong SB, Hernández-Reséndiz S, Crespo-Avilan GE, et al. Inflammation following acute myocardial infarction: multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther. 2018;186:73–87.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022;145(18):e876–e894. doi:10.1161/CIR.0000000000001062
   PubMed Web of Science ®Google Scholar
• Kologrivova I, Shtatolkina M, Suslova T, et al. Cells of the immune system in cardiac remodeling: main players in resolution of inflammation and repair after myocardial infarction. Front Immunol. 2021;12(664457). doi:10.3389/fimmu.2021.664457
   PubMedGoogle Scholar
• Komal S, Komal N, Mujtaba A, et al. Potential therapeutic strategies for myocardial infarction: the role of Toll-like receptors. Immunol Res. 2022;70(5):607–623. doi:10.1007/s12026-022-09290-z
   PubMed Web of Science ®Google Scholar
• Wang X, Li W, Zhang Y, et al. Calycosin as a Novel PI3K activator reduces inflammation and fibrosis in heart failure through AKT-IKK/STAT3 axis. Front Pharmacol. 2022;13:828061.
   PubMed Web of Science ®Google Scholar
• Yang Y, Xu C, Tang S, et al. Interleukin-9 aggravates isoproterenol-induced heart failure by activating signal transducer and activator of transcription 3 signalling. Can J Cardiol. 2020;36(11):1770–1781. doi:10.1016/j.cjca.2020.01.011
   PubMed Web of Science ®Google Scholar
• Szabo TM, Frigy A, Nagy EE. Targeting mediators of inflammation in heart failure: a short synthesis of experimental and clinical results. Int J Mol Sci. 2021;22(23):13053. doi:10.3390/ijms222313053
   PubMed Web of Science ®Google Scholar
• Morante-Palacios O, Fondelli F, Ballestar E, et al. Tolerogenic dendritic cells in autoimmunity and inflammatory diseases. Trends Immunol. 2021;42(1):59–75. doi:10.1016/j.it.2020.11.001
   PubMed Web of Science ®Google Scholar
• Choo EH, Lee JH, Park EH, et al. Infarcted myocardium-primed dendritic cells improve remodeling and cardiac function after myocardial infarction by modulating the regulatory T cell and macrophage polarization. Circulation. 2017;135(15):1444–1457. doi:10.1161/CIRCULATIONAHA.116.023106
   PubMed Web of Science ®Google Scholar
• Cao W, Chen J, Chen Y, et al. Advanced glycation end products promote heart failure through inducing the immune maturation of dendritic cells. Appl Biochem Biotechnol. 2014;172(8):4062–4077. doi:10.1007/s12010-014-0804-7
   PubMed Web of Science ®Google Scholar
• Silvestre-Roig C, Braster Q, Ortega-Gomez A, et al. Neutrophils as regulators of cardiovascular inflammation. Nat Rev Cardiol. 2020;17(6):327–340. doi:10.1038/s41569-019-0326-7
   PubMed Web of Science ®Google Scholar
• Tang X, Wang P, Zhang R, et al. KLF2 regulates neutrophil activation and thrombosis in cardiac hypertrophy and heart failure progression. J Clin Invest. 2022;132(3). doi:10.1172/JCI147191
   Web of Science ®Google Scholar
• Bermea K, Bhalodia A, Huff A, et al. The role of B cells in cardiomyopathy and heart failure. Curr Cardiol Rep. 2022;24(8):935–946. doi:10.1007/s11886-022-01722-4
   PubMed Web of Science ®Google Scholar
• Yang J, Li Y, Sun Z, et al. COL17A1 facilitates tumor growth and predicts poor prognosis in pancreatic cancer. Biochem Biophys Res Commun. 2022;632:1–9.
   PubMed Web of Science ®Google Scholar
• Maag JLV, Fisher OM, Levert-Mignon A, et al. Novel aberrations uncovered in barrett’s esophagus and esophageal adenocarcinoma using whole transcriptome sequencing. Mol Cancer Res. 2017;15(11):1558–1569. doi:10.1158/1541-7786.MCR-17-0332
   PubMed Web of Science ®Google Scholar
• Van den Bergh F, Eliason SL, Burmeister BT, et al. Collagen XVII (BP180) modulates keratinocyte expression of the proinflammatory chemokine, IL-8. Exp Dermatol. 2012;21(8):605–611. doi:10.1111/j.1600-0625.2012.01529.x
   PubMed Web of Science ®Google Scholar
• Lothong M, Sakares W, Rojsitthisak P, et al. Collagen XVII inhibits breast cancer cell proliferation and growth through deactivation of the AKT/mTOR signaling pathway. PLoS One. 2021;16(7):e0255179. doi:10.1371/journal.pone.0255179
   PubMed Web of Science ®Google Scholar
• Nikolov A, Popovski N. Extracellular matrix in heart disease: focus on circulating collagen type I and III derived peptides as biomarkers of myocardial fibrosis and their potential in the prognosis of heart failure: a concise review. Metabolites. 2022;12(4):297. doi:10.3390/metabo12040297
   PubMed Web of Science ®Google Scholar
• Papandreou C, Hernández-Alonso P, Bulló M, et al. High plasma glutamate and a low glutamine-to-glutamate ratio are associated with increased risk of heart failure but not atrial fibrillation in the prevención con dieta mediterránea (PREDIMED) Study. J Nutr. 2020;150(11):2882–2889. doi:10.1093/jn/nxaa273
   PubMed Web of Science ®Google Scholar
• Song J, Meng Y, Wang M, et al. Mangiferin activates Nrf2 to attenuate cardiac fibrosis via redistributing glutaminolysis-derived glutamate. Pharmacol Res. 2020;157(104845):104845. doi:10.1016/j.phrs.2020.104845
   PubMedGoogle Scholar